Takeda India felicitated as one of The Economic Times Best Healthcare Brand 2023

NewsVoir
New Delhi [India], June 30: Takeda Biopharmaceuticals India Pvt. Ltd. (formerly known as Baxalta Bioscience India Private Limited), a global values-based, R&D-driven biopharmaceutical leader has recently been recognized as one of The Economic Times Best Healthcare Brands 2023'. The recognition has been earned by the organization on the basis of innovation, healthcare standards, patient satisfaction, responsibility, and commitment.
The Economic Times Best Healthcare Brands 2023 initiative aims to acknowledge healthcare innovations and bring the efforts of industry leaders to the forefront. Healthcare has become a crucial sector, prompted by the pandemic and the changing global health landscape, which makes innovation and the focus on research and development all the more critical.
On receiving the recognition, Serina Fischer, General Manager, Takeda Biopharmaceuticals India Pvt. Ltd. said, "We are honoured to receive this prestigious recognition as one of The Best Healthcare Brands of 2023 by The Economic Times. This accolade serves as an acknowledgment of our unwavering commitment to our vision of bringing better health and a brighter future worldwide. We will continue our efforts for making a lasting impact on the well-being of people in India while contributing to the transformative journey of healthcare in the years ahead."
Sharing on the same, Dr Ruchi Sogarwal, Head of Corporate Affairs, Takeda Biopharmaceuticals India Pvt. Ltd. said, "The acknowledgement reaffirms our efforts towards our patients through our relentless pursuit of innovation, accessibility, and patient-centricity. Along with ecosystem partners, we are committed to the national and state government policies and initiatives in making healthcare more equitable and inclusive for all."
In its 6th edition this year, the event hosted leading voices from the sector to discuss key concerns such as value-based care, nutritional aspects, role, and the importance of adopting new-age technology among others under the overarching theme of "Exploring the Next in Healthcare".
Acknowledged as one of the Best Places to Work for 2023 and a Global Top Employer for a sixth consecutive year, Takeda India is expanding its footprint in India as a responsible pharmaceutical and healthcare leader. Being a key participator in the G20 meetings, Takeda also showcased its digital innovations targeted to improve the treatment and management of rare diseases in the advancement of their vision to reduce the rare disease burden in India and around the globe.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
For more information, visit

For the purposes of this notice, "press release" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda, directly and indirectly, owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at:
or at
. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.
(Disclaimer: The above press release has been provided by NewsVoir. ANI will not be responsible in any way for the content of the same)